Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far?
Abstract
SGLT2 inhibitors have transformed the care of patients with diabetes, chronic kidney disease (CKD), and cardiovascular disease. Nevertheless, the efficacy of SGLT2 inhibitors as well as potential associated risks remains to be further clarified in the setting of advanced diabetic kidney disease. Indirect evidence and secondary analyses from the landmark SGLT2 trials as well as emerging data from recent studies including exclusively patients with diabetes and advanced CKD, indicate that the renal and cardiovascular benefits of SGLT2 inhibitors persist even in these patients. Although the use of SGLT2 inhibitors in patients with diabetes undergoing dialysis remains investigational, preliminary evidence from experimental and clinical studies seems promising in terms of multifaceted positive outcomes, including preservation of residual kidney function. Furthermore, the available data until now does not indicate an increase in risk in patients with diabetes and advanced CKD regarding acute impairment of kidney function or other adverse outcomes of interest including diabetic ketoacidosis, infections, fractures risk and amputations. The aim of this review is to present the current knowledge available on the utility of SGLT2 inhibitors in patients with diabetes and advanced CKD so as to provide a foundation for their implementation in clinical practice. Future experimental research shall further elucidate the pleiotropic effects of SGLT2 inhibitors so as to expand their indications…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.